

Global Biologics and Biosimilars Market Growth 2023-2029

https://marketpublishers.com/r/G3517AF189CEN.html

Date: January 2023 Pages: 116 Price: US\$ 3,660.00 (Single User License) ID: G3517AF189CEN

Abstracts

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.

A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original "innovator" products, and can be manufactured when the original product's patent expires.

LPI (LP Information)' newest research report, the "Biologics and Biosimilars Industry Forecast" looks at past sales and reviews total world Biologics and Biosimilars sales in 2022, providing a comprehensive analysis by region and market sector of projected Biologics and Biosimilars sales for 2023 through 2029. With Biologics and Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Biologics and Biosimilars industry.

This Insight Report provides a comprehensive analysis of the global Biologics and Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biologics and Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Biologics and Biosimilars market.



This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biologics and Biosimilars and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottomup qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biologics and Biosimilars.

The global Biologics and Biosimilars market size is projected to grow from US\$ 189000 million in 2022 to US\$ 271130 million in 2029; it is expected to grow at a CAGR of 271130 from 2023 to 2029.

The major global manufacturers of biologics and biosimilars are Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, Sansheng Pharmaceuticals, Changchun Gaoxin, CITICS Guojia, Baitai Biotech, Sijin Biotech, Cinda Biotech, Tonghua Dongbao, Ganli and Union Pharmaceuticals, etc. Roche, Amgen and AbbVie are the top three, with a combined market share of about 37%.

This report presents a comprehensive overview, market shares, and growth opportunities of Biologics and Biosimilars market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Monoclonal Antibodies

Interferon

Erythropoietin

Insulin

Vaccines

Others



Segmentation by application

Tumor

Diabetes

Cardiovascular

Hemophilia

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia



Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Roche Amgen AbbVie Sanofi-Aventis Johnson & Johnson



Pfizer

Novo Nordisk

Eli Lilly

Novartis

Merck

3sbio

Changchun High Tech

CP Guojian

Biotech

Gelgen

Innovent

Dong Bao

Ganlee

United Laboratories

Key Questions Addressed in this Report

What is the 10-year outlook for the global Biologics and Biosimilars market?

What factors are driving Biologics and Biosimilars market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Biologics and Biosimilars market opportunities vary by end market size?



How does Biologics and Biosimilars break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?



Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Biologics and Biosimilars Annual Sales 2018-2029
- 2.1.2 World Current & Future Analysis for Biologics and Biosimilars by Geographic Region, 2018, 2022 & 2029
- 2.1.3 World Current & Future Analysis for Biologics and Biosimilars by

Country/Region, 2018, 2022 & 2029

- 2.2 Biologics and Biosimilars Segment by Type
 - 2.2.1 Monoclonal Antibodies
 - 2.2.2 Interferon
 - 2.2.3 Erythropoietin
 - 2.2.4 Insulin
 - 2.2.5 Vaccines
 - 2.2.6 Others
- 2.3 Biologics and Biosimilars Sales by Type
- 2.3.1 Global Biologics and Biosimilars Sales Market Share by Type (2018-2023)
- 2.3.2 Global Biologics and Biosimilars Revenue and Market Share by Type
- (2018-2023)
- 2.3.3 Global Biologics and Biosimilars Sale Price by Type (2018-2023)
- 2.4 Biologics and Biosimilars Segment by Application
 - 2.4.1 Tumor
 - 2.4.2 Diabetes
 - 2.4.3 Cardiovascular
 - 2.4.4 Hemophilia
 - 2.4.5 Others



- 2.5 Biologics and Biosimilars Sales by Application
- 2.5.1 Global Biologics and Biosimilars Sale Market Share by Application (2018-2023)

2.5.2 Global Biologics and Biosimilars Revenue and Market Share by Application (2018-2023)

2.5.3 Global Biologics and Biosimilars Sale Price by Application (2018-2023)

3 GLOBAL BIOLOGICS AND BIOSIMILARS BY COMPANY

3.1 Global Biologics and Biosimilars Breakdown Data by Company

- 3.1.1 Global Biologics and Biosimilars Annual Sales by Company (2018-2023)
- 3.1.2 Global Biologics and Biosimilars Sales Market Share by Company (2018-2023)
- 3.2 Global Biologics and Biosimilars Annual Revenue by Company (2018-2023)
- 3.2.1 Global Biologics and Biosimilars Revenue by Company (2018-2023)

3.2.2 Global Biologics and Biosimilars Revenue Market Share by Company (2018-2023)

3.3 Global Biologics and Biosimilars Sale Price by Company

3.4 Key Manufacturers Biologics and Biosimilars Producing Area Distribution, Sales Area, Product Type

- 3.4.1 Key Manufacturers Biologics and Biosimilars Product Location Distribution
- 3.4.2 Players Biologics and Biosimilars Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR BIOLOGICS AND BIOSIMILARS BY GEOGRAPHIC REGION

4.1 World Historic Biologics and Biosimilars Market Size by Geographic Region (2018-2023)

4.1.1 Global Biologics and Biosimilars Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Biologics and Biosimilars Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Biologics and Biosimilars Market Size by Country/Region (2018-2023)

- 4.2.1 Global Biologics and Biosimilars Annual Sales by Country/Region (2018-2023)
- 4.2.2 Global Biologics and Biosimilars Annual Revenue by Country/Region



(2018-2023)

- 4.3 Americas Biologics and Biosimilars Sales Growth
- 4.4 APAC Biologics and Biosimilars Sales Growth
- 4.5 Europe Biologics and Biosimilars Sales Growth
- 4.6 Middle East & Africa Biologics and Biosimilars Sales Growth

5 AMERICAS

- 5.1 Americas Biologics and Biosimilars Sales by Country
- 5.1.1 Americas Biologics and Biosimilars Sales by Country (2018-2023)
- 5.1.2 Americas Biologics and Biosimilars Revenue by Country (2018-2023)
- 5.2 Americas Biologics and Biosimilars Sales by Type
- 5.3 Americas Biologics and Biosimilars Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Biologics and Biosimilars Sales by Region
- 6.1.1 APAC Biologics and Biosimilars Sales by Region (2018-2023)
- 6.1.2 APAC Biologics and Biosimilars Revenue by Region (2018-2023)
- 6.2 APAC Biologics and Biosimilars Sales by Type
- 6.3 APAC Biologics and Biosimilars Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Biologics and Biosimilars by Country
- 7.1.1 Europe Biologics and Biosimilars Sales by Country (2018-2023)
- 7.1.2 Europe Biologics and Biosimilars Revenue by Country (2018-2023)
- 7.2 Europe Biologics and Biosimilars Sales by Type



- 7.3 Europe Biologics and Biosimilars Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Biologics and Biosimilars by Country
- 8.1.1 Middle East & Africa Biologics and Biosimilars Sales by Country (2018-2023)
- 8.1.2 Middle East & Africa Biologics and Biosimilars Revenue by Country (2018-2023)
- 8.2 Middle East & Africa Biologics and Biosimilars Sales by Type
- 8.3 Middle East & Africa Biologics and Biosimilars Sales by Application

8.4 Egypt

- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Biologics and Biosimilars
- 10.3 Manufacturing Process Analysis of Biologics and Biosimilars
- 10.4 Industry Chain Structure of Biologics and Biosimilars

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels
 - 11.1.2 Indirect Channels
- 11.2 Biologics and Biosimilars Distributors



11.3 Biologics and Biosimilars Customer

12 WORLD FORECAST REVIEW FOR BIOLOGICS AND BIOSIMILARS BY GEOGRAPHIC REGION

12.1 Global Biologics and Biosimilars Market Size Forecast by Region

12.1.1 Global Biologics and Biosimilars Forecast by Region (2024-2029)

12.1.2 Global Biologics and Biosimilars Annual Revenue Forecast by Region (2024-2029)

- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Biologics and Biosimilars Forecast by Type
- 12.7 Global Biologics and Biosimilars Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Roche

- 13.1.1 Roche Company Information
- 13.1.2 Roche Biologics and Biosimilars Product Portfolios and Specifications
- 13.1.3 Roche Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.1.4 Roche Main Business Overview
 - 13.1.5 Roche Latest Developments

13.2 Amgen

- 13.2.1 Amgen Company Information
- 13.2.2 Amgen Biologics and Biosimilars Product Portfolios and Specifications
- 13.2.3 Amgen Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.2.4 Amgen Main Business Overview
- 13.2.5 Amgen Latest Developments

13.3 AbbVie

- 13.3.1 AbbVie Company Information
- 13.3.2 AbbVie Biologics and Biosimilars Product Portfolios and Specifications
- 13.3.3 AbbVie Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.3.4 AbbVie Main Business Overview
- 13.3.5 AbbVie Latest Developments



13.4 Sanofi-Aventis

13.4.1 Sanofi-Aventis Company Information

13.4.2 Sanofi-Aventis Biologics and Biosimilars Product Portfolios and Specifications

13.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 Sanofi-Aventis Main Business Overview

13.4.5 Sanofi-Aventis Latest Developments

13.5 Johnson & Johnson

13.5.1 Johnson & Johnson Company Information

13.5.2 Johnson & Johnson Biologics and Biosimilars Product Portfolios and Specifications

13.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)

13.5.4 Johnson & Johnson Main Business Overview

13.5.5 Johnson & Johnson Latest Developments

13.6 Pfizer

13.6.1 Pfizer Company Information

13.6.2 Pfizer Biologics and Biosimilars Product Portfolios and Specifications

13.6.3 Pfizer Biologics and Biosimilars Sales, Revenue, Price and Gross Margin

(2018-2023)

13.6.4 Pfizer Main Business Overview

13.6.5 Pfizer Latest Developments

13.7 Novo Nordisk

13.7.1 Novo Nordisk Company Information

13.7.2 Novo Nordisk Biologics and Biosimilars Product Portfolios and Specifications

13.7.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)

13.7.4 Novo Nordisk Main Business Overview

13.7.5 Novo Nordisk Latest Developments

13.8 Eli Lilly

- 13.8.1 Eli Lilly Company Information
- 13.8.2 Eli Lilly Biologics and Biosimilars Product Portfolios and Specifications

13.8.3 Eli Lilly Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)

13.8.4 Eli Lilly Main Business Overview

13.8.5 Eli Lilly Latest Developments

13.9 Novartis

13.9.1 Novartis Company Information

13.9.2 Novartis Biologics and Biosimilars Product Portfolios and Specifications



13.9.3 Novartis Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)

13.9.4 Novartis Main Business Overview

13.9.5 Novartis Latest Developments

13.10 Merck

13.10.1 Merck Company Information

13.10.2 Merck Biologics and Biosimilars Product Portfolios and Specifications

13.10.3 Merck Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)

13.10.4 Merck Main Business Overview

13.10.5 Merck Latest Developments

13.11 3sbio

13.11.1 3sbio Company Information

13.11.2 3sbio Biologics and Biosimilars Product Portfolios and Specifications

13.11.3 3sbio Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)

13.11.4 3sbio Main Business Overview

13.11.5 3sbio Latest Developments

13.12 Changchun High Tech

13.12.1 Changchun High Tech Company Information

13.12.2 Changchun High Tech Biologics and Biosimilars Product Portfolios and Specifications

13.12.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)

13.12.4 Changchun High Tech Main Business Overview

13.12.5 Changchun High Tech Latest Developments

13.13 CP Guojian

13.13.1 CP Guojian Company Information

13.13.2 CP Guojian Biologics and Biosimilars Product Portfolios and Specifications

13.13.3 CP Guojian Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)

13.13.4 CP Guojian Main Business Overview

13.13.5 CP Guojian Latest Developments

13.14 Biotech

13.14.1 Biotech Company Information

13.14.2 Biotech Biologics and Biosimilars Product Portfolios and Specifications

13.14.3 Biotech Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)

13.14.4 Biotech Main Business Overview



- 13.14.5 Biotech Latest Developments
- 13.15 Gelgen
- 13.15.1 Gelgen Company Information
- 13.15.2 Gelgen Biologics and Biosimilars Product Portfolios and Specifications
- 13.15.3 Gelgen Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.15.4 Gelgen Main Business Overview
 - 13.15.5 Gelgen Latest Developments

13.16 Innovent

- 13.16.1 Innovent Company Information
- 13.16.2 Innovent Biologics and Biosimilars Product Portfolios and Specifications
- 13.16.3 Innovent Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.16.4 Innovent Main Business Overview
- 13.16.5 Innovent Latest Developments

13.17 Dong Bao

- 13.17.1 Dong Bao Company Information
- 13.17.2 Dong Bao Biologics and Biosimilars Product Portfolios and Specifications
- 13.17.3 Dong Bao Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.17.4 Dong Bao Main Business Overview
- 13.17.5 Dong Bao Latest Developments
- 13.18 Ganlee
- 13.18.1 Ganlee Company Information
- 13.18.2 Ganlee Biologics and Biosimilars Product Portfolios and Specifications
- 13.18.3 Ganlee Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.18.4 Ganlee Main Business Overview
- 13.18.5 Ganlee Latest Developments
- 13.19 United Laboratories
- 13.19.1 United Laboratories Company Information
- 13.19.2 United Laboratories Biologics and Biosimilars Product Portfolios and Specifications
- 13.19.3 United Laboratories Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.19.4 United Laboratories Main Business Overview
 - 13.19.5 United Laboratories Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION



List Of Tables

LIST OF TABLES

Table 1. Biologics and Biosimilars Annual Sales CAGR by Geographic Region (2018,

2022 & 2029) & (\$ millions)

Table 2. Biologics and Biosimilars Annual Sales CAGR by Country/Region (2018, 2022

& 2029) & (\$ millions)

Table 3. Major Players of Monoclonal Antibodies

Table 4. Major Players of Interferon

Table 5. Major Players of Erythropoietin

Table 6. Major Players of Insulin

Table 7. Major Players of Vaccines

Table 8. Major Players of Others

Table 9. Global Biologics and Biosimilars Sales by Type (2018-2023) & (K Units)

Table 10. Global Biologics and Biosimilars Sales Market Share by Type (2018-2023)

Table 11. Global Biologics and Biosimilars Revenue by Type (2018-2023) & (\$ million)

Table 12. Global Biologics and Biosimilars Revenue Market Share by Type (2018-2023)

Table 13. Global Biologics and Biosimilars Sale Price by Type (2018-2023) & (USD/Unit)

Table 14. Global Biologics and Biosimilars Sales by Application (2018-2023) & (K Units) Table 15. Global Biologics and Biosimilars Sales Market Share by Application (2018-2023)

Table 16. Global Biologics and Biosimilars Revenue by Application (2018-2023) Table 17. Global Biologics and Biosimilars Revenue Market Share by Application (2018-2023)

Table 18. Global Biologics and Biosimilars Sale Price by Application (2018-2023) & (USD/Unit)

Table 19. Global Biologics and Biosimilars Sales by Company (2018-2023) & (K Units) Table 20. Global Biologics and Biosimilars Sales Market Share by Company (2018-2023)

Table 21. Global Biologics and Biosimilars Revenue by Company (2018-2023) (\$ Millions)

Table 22. Global Biologics and Biosimilars Revenue Market Share by Company (2018-2023)

Table 23. Global Biologics and Biosimilars Sale Price by Company (2018-2023) & (USD/Unit)

Table 24. Key Manufacturers Biologics and Biosimilars Producing Area Distribution and Sales Area



Table 25. Players Biologics and Biosimilars Products Offered Table 26. Biologics and Biosimilars Concentration Ratio (CR3, CR5 and CR10) & (2018 - 2023)Table 27. New Products and Potential Entrants Table 28. Mergers & Acquisitions, Expansion Table 29. Global Biologics and Biosimilars Sales by Geographic Region (2018-2023) & (K Units) Table 30. Global Biologics and Biosimilars Sales Market Share Geographic Region (2018 - 2023)Table 31. Global Biologics and Biosimilars Revenue by Geographic Region (2018-2023) & (\$ millions) Table 32. Global Biologics and Biosimilars Revenue Market Share by Geographic Region (2018-2023) Table 33. Global Biologics and Biosimilars Sales by Country/Region (2018-2023) & (K Units) Table 34. Global Biologics and Biosimilars Sales Market Share by Country/Region (2018 - 2023)Table 35. Global Biologics and Biosimilars Revenue by Country/Region (2018-2023) & (\$ millions) Table 36. Global Biologics and Biosimilars Revenue Market Share by Country/Region (2018 - 2023)Table 37. Americas Biologics and Biosimilars Sales by Country (2018-2023) & (K Units) Table 38. Americas Biologics and Biosimilars Sales Market Share by Country (2018 - 2023)Table 39. Americas Biologics and Biosimilars Revenue by Country (2018-2023) & (\$ Millions) Table 40. Americas Biologics and Biosimilars Revenue Market Share by Country (2018 - 2023)Table 41. Americas Biologics and Biosimilars Sales by Type (2018-2023) & (K Units) Table 42. Americas Biologics and Biosimilars Sales by Application (2018-2023) & (K Units) Table 43. APAC Biologics and Biosimilars Sales by Region (2018-2023) & (K Units) Table 44. APAC Biologics and Biosimilars Sales Market Share by Region (2018-2023) Table 45. APAC Biologics and Biosimilars Revenue by Region (2018-2023) & (\$ Millions) Table 46. APAC Biologics and Biosimilars Revenue Market Share by Region (2018 - 2023)Table 47. APAC Biologics and Biosimilars Sales by Type (2018-2023) & (K Units) Table 48. APAC Biologics and Biosimilars Sales by Application (2018-2023) & (K Units)



Table 49. Europe Biologics and Biosimilars Sales by Country (2018-2023) & (K Units) Table 50. Europe Biologics and Biosimilars Sales Market Share by Country (2018-2023) Table 51. Europe Biologics and Biosimilars Revenue by Country (2018-2023) & (\$ Millions) Table 52. Europe Biologics and Biosimilars Revenue Market Share by Country (2018 - 2023)Table 53. Europe Biologics and Biosimilars Sales by Type (2018-2023) & (K Units) Table 54. Europe Biologics and Biosimilars Sales by Application (2018-2023) & (K Units) Table 55. Middle East & Africa Biologics and Biosimilars Sales by Country (2018-2023) & (K Units) Table 56. Middle East & Africa Biologics and Biosimilars Sales Market Share by Country (2018-2023)Table 57. Middle East & Africa Biologics and Biosimilars Revenue by Country (2018-2023) & (\$ Millions) Table 58. Middle East & Africa Biologics and Biosimilars Revenue Market Share by Country (2018-2023) Table 59. Middle East & Africa Biologics and Biosimilars Sales by Type (2018-2023) & (K Units) Table 60. Middle East & Africa Biologics and Biosimilars Sales by Application (2018-2023) & (K Units) Table 61. Key Market Drivers & Growth Opportunities of Biologics and Biosimilars Table 62. Key Market Challenges & Risks of Biologics and Biosimilars Table 63. Key Industry Trends of Biologics and Biosimilars Table 64. Biologics and Biosimilars Raw Material Table 65. Key Suppliers of Raw Materials Table 66. Biologics and Biosimilars Distributors List Table 67. Biologics and Biosimilars Customer List Table 68. Global Biologics and Biosimilars Sales Forecast by Region (2024-2029) & (K Units) Table 69. Global Biologics and Biosimilars Revenue Forecast by Region (2024-2029) & (\$ millions) Table 70. Americas Biologics and Biosimilars Sales Forecast by Country (2024-2029) & (K Units) Table 71. Americas Biologics and Biosimilars Revenue Forecast by Country (2024-2029) & (\$ millions) Table 72. APAC Biologics and Biosimilars Sales Forecast by Region (2024-2029) & (K Units) Table 73. APAC Biologics and Biosimilars Revenue Forecast by Region (2024-2029) &



(\$ millions)

Table 74. Europe Biologics and Biosimilars Sales Forecast by Country (2024-2029) & (K Units)

Table 75. Europe Biologics and Biosimilars Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 76. Middle East & Africa Biologics and Biosimilars Sales Forecast by Country (2024-2029) & (K Units)

Table 77. Middle East & Africa Biologics and Biosimilars Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 78. Global Biologics and Biosimilars Sales Forecast by Type (2024-2029) & (K Units)

Table 79. Global Biologics and Biosimilars Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 80. Global Biologics and Biosimilars Sales Forecast by Application (2024-2029) & (K Units)

Table 81. Global Biologics and Biosimilars Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 82. Roche Basic Information, Biologics and Biosimilars Manufacturing Base,

Sales Area and Its Competitors

Table 83. Roche Biologics and Biosimilars Product Portfolios and Specifications

Table 84. Roche Biologics and Biosimilars Sales (K Units), Revenue (\$ Million), Price

(USD/Unit) and Gross Margin (2018-2023)

Table 85. Roche Main Business

Table 86. Roche Latest Developments

Table 87. Amgen Basic Information, Biologics and Biosimilars Manufacturing Base,

Sales Area and Its Competitors

Table 88. Amgen Biologics and Biosimilars Product Portfolios and Specifications

Table 89. Amgen Biologics and Biosimilars Sales (K Units), Revenue (\$ Million), Price

(USD/Unit) and Gross Margin (2018-2023)

Table 90. Amgen Main Business

Table 91. Amgen Latest Developments

Table 92. AbbVie Basic Information, Biologics and Biosimilars Manufacturing Base,

Sales Area and Its Competitors

Table 93. AbbVie Biologics and Biosimilars Product Portfolios and Specifications

Table 94. AbbVie Biologics and Biosimilars Sales (K Units), Revenue (\$ Million), Price

(USD/Unit) and Gross Margin (2018-2023)

Table 95. AbbVie Main Business

Table 96. AbbVie Latest Developments

Table 97. Sanofi-Aventis Basic Information, Biologics and Biosimilars Manufacturing



Base, Sales Area and Its Competitors Table 98. Sanofi-Aventis Biologics and Biosimilars Product Portfolios and Specifications Table 99. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 100. Sanofi-Aventis Main Business Table 101. Sanofi-Aventis Latest Developments Table 102. Johnson & Johnson Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 103. Johnson & Johnson Biologics and Biosimilars Product Portfolios and **Specifications** Table 104. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 105. Johnson & Johnson Main Business Table 106. Johnson & Johnson Latest Developments Table 107. Pfizer Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 108. Pfizer Biologics and Biosimilars Product Portfolios and Specifications Table 109. Pfizer Biologics and Biosimilars Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 110. Pfizer Main Business Table 111. Pfizer Latest Developments Table 112. Novo Nordisk Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 113. Novo Nordisk Biologics and Biosimilars Product Portfolios and Specifications Table 114. Novo Nordisk Biologics and Biosimilars Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 115. Novo Nordisk Main Business Table 116. Novo Nordisk Latest Developments Table 117. Eli Lilly Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 118. Eli Lilly Biologics and Biosimilars Product Portfolios and Specifications Table 119. Eli Lilly Biologics and Biosimilars Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 120. Eli Lilly Main Business Table 121. Eli Lilly Latest Developments Table 122. Novartis Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 123. Novartis Biologics and Biosimilars Product Portfolios and Specifications Table 124. Novartis Biologics and Biosimilars Sales (K Units), Revenue (\$ Million), Price



(USD/Unit) and Gross Margin (2018-2023)

- Table 125. Novartis Main Business
- Table 126. Novartis Latest Developments

Table 127. Merck Basic Information, Biologics and Biosimilars Manufacturing Base,

- Sales Area and Its Competitors
- Table 128. Merck Biologics and Biosimilars Product Portfolios and Specifications
- Table 129. Merck Biologics and Biosimilars Sales (K Units), Revenue (\$ Million), Price
- (USD/Unit) and Gross Margin (2018-2023)
- Table 130. Merck Main Business
- Table 131. Merck Latest Developments
- Table 132. 3sbio Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
- Table 133. 3sbio Biologics and Biosimilars Product Portfolios and Specifications
- Table 134. 3sbio Biologics and Biosimilars Sales (K Units), Revenue (\$ Million), Price
- (USD/Unit) and Gross Margin (2018-2023)
- Table 135. 3sbio Main Business
- Table 136. 3sbio Latest Developments
- Table 137. Changchun High Tech Basic Information, Biologics and Biosimilars
- Manufacturing Base, Sales Area and Its Competitors
- Table 138. Changchun High Tech Biologics and Biosimilars Product Portfolios and Specifications
- Table 139. Changchun High Tech Biologics and Biosimilars Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
- Table 140. Changchun High Tech Main Business
- Table 141. Changchun High Tech Latest Developments
- Table 142. CP Guojian Basic Information, Biologics and Biosimilars Manufacturing
- Base, Sales Area and Its Competitors
- Table 143. CP Guojian Biologics and Biosimilars Product Portfolios and Specifications
- Table 144. CP Guojian Biologics and Biosimilars Sales (K Units), Revenue (\$ Million),
- Price (USD/Unit) and Gross Margin (2018-2023)
- Table 145. CP Guojian Main Business
- Table 146. CP Guojian Latest Developments
- Table 147. Biotech Basic Information, Biologics and Biosimilars Manufacturing Base,
- Sales Area and Its Competitors
- Table 148. Biotech Biologics and Biosimilars Product Portfolios and Specifications
- Table 149. Biotech Biologics and Biosimilars Sales (K Units), Revenue (\$ Million), Price
- (USD/Unit) and Gross Margin (2018-2023)
- Table 150. Biotech Main Business
- Table 151. Biotech Latest Developments



Table 152. Gelgen Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors

 Table 153. Gelgen Biologics and Biosimilars Product Portfolios and Specifications

Table 154. Gelgen Biologics and Biosimilars Sales (K Units), Revenue (\$ Million), Price

(USD/Unit) and Gross Margin (2018-2023)

Table 155. Gelgen Main Business

Table 156. Gelgen Latest Developments

Table 157. Innovent Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors

Table 158. Innovent Biologics and Biosimilars Product Portfolios and Specifications

Table 159. Innovent Biologics and Biosimilars Sales (K Units), Revenue (\$ Million),

Price (USD/Unit) and Gross Margin (2018-2023)

Table 160. Innovent Main Business

Table 161. Innovent Latest Developments

Table 162. Dong Bao Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors

Table 163. Dong Bao Biologics and Biosimilars Product Portfolios and Specifications

Table 164. Dong Bao Biologics and Biosimilars Sales (K Units), Revenue (\$ Million),

Price (USD/Unit) and Gross Margin (2018-2023)

Table 165. Dong Bao Main Business

Table 166. Dong Bao Latest Developments

Table 167. Ganlee Basic Information, Biologics and Biosimilars Manufacturing Base,

Sales Area and Its Competitors

 Table 168. Ganlee Biologics and Biosimilars Product Portfolios and Specifications

Table 169. Ganlee Biologics and Biosimilars Sales (K Units), Revenue (\$ Million), Price

(USD/Unit) and Gross Margin (2018-2023)

Table 170. Ganlee Main Business

Table 171. Ganlee Latest Developments

Table 172. United Laboratories Basic Information, Biologics and Biosimilars

Manufacturing Base, Sales Area and Its Competitors

Table 173. United Laboratories Biologics and Biosimilars Product Portfolios and Specifications

Table 174. United Laboratories Biologics and Biosimilars Sales (K Units), Revenue (\$

Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 175. United Laboratories Main Business

Table 176. United Laboratories Latest Developments



List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Biologics and Biosimilars
- Figure 2. Biologics and Biosimilars Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Biologics and Biosimilars Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Biologics and Biosimilars Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Biologics and Biosimilars Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Monoclonal Antibodies
- Figure 10. Product Picture of Interferon
- Figure 11. Product Picture of Erythropoietin
- Figure 12. Product Picture of Insulin
- Figure 13. Product Picture of Vaccines
- Figure 14. Product Picture of Others
- Figure 15. Global Biologics and Biosimilars Sales Market Share by Type in 2022
- Figure 16. Global Biologics and Biosimilars Revenue Market Share by Type (2018-2023)
- Figure 17. Biologics and Biosimilars Consumed in Tumor
- Figure 18. Global Biologics and Biosimilars Market: Tumor (2018-2023) & (K Units)
- Figure 19. Biologics and Biosimilars Consumed in Diabetes
- Figure 20. Global Biologics and Biosimilars Market: Diabetes (2018-2023) & (K Units)
- Figure 21. Biologics and Biosimilars Consumed in Cardiovascular
- Figure 22. Global Biologics and Biosimilars Market: Cardiovascular (2018-2023) & (K Units)
- Figure 23. Biologics and Biosimilars Consumed in Hemophilia
- Figure 24. Global Biologics and Biosimilars Market: Hemophilia (2018-2023) & (K Units)
- Figure 25. Biologics and Biosimilars Consumed in Others
- Figure 26. Global Biologics and Biosimilars Market: Others (2018-2023) & (K Units)
- Figure 27. Global Biologics and Biosimilars Sales Market Share by Application (2022)
- Figure 28. Global Biologics and Biosimilars Revenue Market Share by Application in 2022
- Figure 29. Biologics and Biosimilars Sales Market by Company in 2022 (K Units)
- Figure 30. Global Biologics and Biosimilars Sales Market Share by Company in 2022
- Figure 31. Biologics and Biosimilars Revenue Market by Company in 2022 (\$ Million)
- Figure 32. Global Biologics and Biosimilars Revenue Market Share by Company in



2022

Figure 33. Global Biologics and Biosimilars Sales Market Share by Geographic Region (2018-2023)

Figure 34. Global Biologics and Biosimilars Revenue Market Share by Geographic Region in 2022

Figure 35. Americas Biologics and Biosimilars Sales 2018-2023 (K Units)

Figure 36. Americas Biologics and Biosimilars Revenue 2018-2023 (\$ Millions)

Figure 37. APAC Biologics and Biosimilars Sales 2018-2023 (K Units)

Figure 38. APAC Biologics and Biosimilars Revenue 2018-2023 (\$ Millions)

Figure 39. Europe Biologics and Biosimilars Sales 2018-2023 (K Units)

Figure 40. Europe Biologics and Biosimilars Revenue 2018-2023 (\$ Millions)

Figure 41. Middle East & Africa Biologics and Biosimilars Sales 2018-2023 (K Units)

Figure 42. Middle East & Africa Biologics and Biosimilars Revenue 2018-2023 (\$ Millions)

Figure 43. Americas Biologics and Biosimilars Sales Market Share by Country in 2022

Figure 44. Americas Biologics and Biosimilars Revenue Market Share by Country in 2022

Figure 45. Americas Biologics and Biosimilars Sales Market Share by Type (2018-2023) Figure 46. Americas Biologics and Biosimilars Sales Market Share by Application (2018-2023)

Figure 47. United States Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions)

Figure 48. Canada Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions)

Figure 49. Mexico Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions)

Figure 50. Brazil Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions)

Figure 51. APAC Biologics and Biosimilars Sales Market Share by Region in 2022

Figure 52. APAC Biologics and Biosimilars Revenue Market Share by Regions in 2022

Figure 53. APAC Biologics and Biosimilars Sales Market Share by Type (2018-2023) Figure 54. APAC Biologics and Biosimilars Sales Market Share by Application

(2018-2023)

Figure 55. China Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions)

Figure 56. Japan Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions)

Figure 57. South Korea Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions)

Figure 58. Southeast Asia Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions)

Figure 59. India Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions) Figure 60. Australia Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions) Figure 61. China Taiwan Biologics and Biosimilars Revenue Growth 2018-2023 (\$



Millions)

Figure 62. Europe Biologics and Biosimilars Sales Market Share by Country in 2022

Figure 63. Europe Biologics and Biosimilars Revenue Market Share by Country in 2022

Figure 64. Europe Biologics and Biosimilars Sales Market Share by Type (2018-2023)

Figure 65. Europe Biologics and Biosimilars Sales Market Share by Application (2018-2023)

Figure 66. Germany Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions)

Figure 67. France Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions)

Figure 68. UK Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions)

Figure 69. Italy Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions)

Figure 70. Russia Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions)

Figure 71. Middle East & Africa Biologics and Biosimilars Sales Market Share by Country in 2022

Figure 72. Middle East & Africa Biologics and Biosimilars Revenue Market Share by Country in 2022

Figure 73. Middle East & Africa Biologics and Biosimilars Sales Market Share by Type (2018-2023)

Figure 74. Middle East & Africa Biologics and Biosimilars Sales Market Share by Application (2018-2023)

Figure 75. Egypt Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions)

Figure 76. South Africa Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions)

Figure 77. Israel Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions)

Figure 78. Turkey Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions)

Figure 79. GCC Country Biologics and Biosimilars Revenue Growth 2018-2023 (\$ Millions)

Figure 80. Manufacturing Cost Structure Analysis of Biologics and Biosimilars in 2022

Figure 81. Manufacturing Process Analysis of Biologics and Biosimilars

Figure 82. Industry Chain Structure of Biologics and Biosimilars

Figure 83. Channels of Distribution

Figure 84. Global Biologics and Biosimilars Sales Market Forecast by Region (2024-2029)

Figure 85. Global Biologics and Biosimilars Revenue Market Share Forecast by Region (2024-2029)

Figure 86. Global Biologics and Biosimilars Sales Market Share Forecast by Type (2024-2029)

Figure 87. Global Biologics and Biosimilars Revenue Market Share Forecast by Type (2024-2029)

Figure 88. Global Biologics and Biosimilars Sales Market Share Forecast by Application



(2024-2029) Figure 89. Global Biologics and Biosimilars Revenue Market Share Forecast by Application (2024-2029)



I would like to order

Product name: Global Biologics and Biosimilars Market Growth 2023-2029

Product link: https://marketpublishers.com/r/G3517AF189CEN.html

Price: US\$ 3,660.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/G3517AF189CEN.html</u>